President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Disc Medicine receives FDA's Commissioner's National Priority Voucher for bitopertin, accelerating approval timeline to 1-2 months for EPP patients who suffer severe sun sensitivity.
President Trump announces new employer-focused IVF initiative to reduce fertility treatment costs. Voluntary program aims to expand workplace coverage options.
Praxis Precision Medicines stock rallied over 170% after its experimental essential tremor treatment ulixacaltamide exceeded expectations in two Phase 3 trials, defying earlier pessimism.
H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.
Tempus AI and Whitehawk Therapeutics announce multi-year collaboration using AI and real-world data to develop targeted antibody drug conjugate therapies for cancer patients.
